Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YW17 (Herozyme) vs Aldurazyme in MPS I
NCT06406153Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of laronidase in mucopolysaccharidosis type I, sponsored by CinnaGen. Primary endpoint: mean urinary glycosaminoglycan levels at Week 24. Started Sep 2022; status: completed.
02
Drugs
laronidase
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT06406153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406153.